David Sebastien Fradet

Title: David Sebastien Fradet: Innovator in Melanocortin Agonists

Introduction

David Sebastien Fradet is a notable inventor based in Sandwich, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of melanocortin receptor agonists. His work has implications for various medical applications, showcasing his innovative spirit and dedication to advancing science.

Latest Patents

Fradet holds a patent for a class of compounds known as (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives, which serve as MCR4 agonists. This invention relates to selective MCR4 agonist compounds, their medicinal uses, compositions containing them, and the processes for their preparation. The patent highlights the potential of these compounds in therapeutic applications.

Career Highlights

David Sebastien Fradet is associated with Pfizer Corporation, a leading global pharmaceutical company. His role at Pfizer has allowed him to collaborate with other talented professionals in the field. His innovative work has contributed to the company's research and development efforts.

Collaborations

Fradet has worked alongside notable colleagues such as David Hepworth and Mark Ian Lansdell. These collaborations have fostered a productive environment for innovation and have led to advancements in their respective fields.

Conclusion

David Sebastien Fradet is a distinguished inventor whose work in melanocortin receptor agonists has the potential to impact medical science significantly. His contributions to Pfizer Corporation and collaborations with esteemed colleagues further underscore his importance in the field of medicinal chemistry.